Evenamide Clinical Trials (2026): 3 Studies for Healthy & Schizophrenia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 Evenamide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Healthy & Schizophrenia) and 544 total planned enrollment. 1 Phase 3 Evenamide trial and 1 Phase 2 are listed. 1 Evenamide clinical trial is actively recruiting. Most recent activity: NCT07184619 (Dec 2026).
Evenamide clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | unknown | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 1 | 1 | ||
| P3 | 1 | 1 |
Recruiting Evenamide clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07184619 | ENIGMA-TRS 2Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | P3 | Treatment-resistant Schizophrenia | 400 | Jan 2026 |
Evenamide clinical trials by indication
Treatment-resistant Schizophrenia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07184619 | ENIGMA-TRS 2 | P3 | recruiting | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia |
Schizophrenia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04461119 | — | P2 | completed | Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03446274 | — | P1 | unknown | An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects |
Evenamide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ENIGMA-TRS 2 | NCT07184619 | P3 | recruiting | Treatment-resistant Schizophrenia | 400 | PMID 39708914 |
All Evenamide trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07184619 | ENIGMA-TRS 2 | Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | P3 | recruiting | 400 | Newron Pharmaceuticals SPA | Jan 2026 |
| NCT04461119 | Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia | P2 | completed | 138 | Newron Pharmaceuticals SPA | Jun 2020 | |
| NCT03446274 | An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects | P1 | unknown | 6 | Newron Pharmaceuticals SPA | Apr 2018 |
Evenamide clinical trials: frequently asked questions
- How many Evenamide clinical trials are there?
- 3 Evenamide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 1 is marked completed.
- Are Evenamide clinical trials recruiting in 2026?
- Yes — 1 Evenamide trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Evenamide being studied for?
- Evenamide is being studied for Healthy, Schizophrenia, Treatment-resistant Schizophrenia. The trials are grouped by indication on this page.
- What phase is Evenamide in?
- Evenamide clinical trials span 1 Phase 3, 1 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Evenamide clinical trials?
- The lead sponsor across the most Evenamide trials is Newron Pharmaceuticals SPA. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Evenamideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: